These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
673 related articles for article (PubMed ID: 16566600)
1. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin. Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600 [TBL] [Abstract][Full Text] [Related]
3. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. Liu JN; Gurewich V J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471 [TBL] [Abstract][Full Text] [Related]
4. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis. Parise P; Morini M; Agnelli G; Ascani A; Nenci GG Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721 [TBL] [Abstract][Full Text] [Related]
5. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Guimarães AH; Rijken DC Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222 [TBL] [Abstract][Full Text] [Related]
6. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin. Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822 [TBL] [Abstract][Full Text] [Related]
7. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727 [TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. Collen D J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213 [TBL] [Abstract][Full Text] [Related]
9. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin. Doolittle RF; Pandi L Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759 [TBL] [Abstract][Full Text] [Related]
10. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system. Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694 [TBL] [Abstract][Full Text] [Related]
11. Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release). Galanakis DK; Neerman-Arbez M; Kudryk B; Henschen A Blood Coagul Fibrinolysis; 2010 Mar; 21(2):135-9. PubMed ID: 20019599 [TBL] [Abstract][Full Text] [Related]
12. Influence of homocysteine on fibrin network lysis. Lauricella AM; Quintana I; Castañon M; Sassetti B; Kordich L Blood Coagul Fibrinolysis; 2006 Apr; 17(3):181-6. PubMed ID: 16575255 [TBL] [Abstract][Full Text] [Related]
13. Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots. Tran-Thang C; Kruithof EK; Bachmann F J Clin Invest; 1984 Dec; 74(6):2009-16. PubMed ID: 6210307 [TBL] [Abstract][Full Text] [Related]
14. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II). Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304 [TBL] [Abstract][Full Text] [Related]
15. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions. Wu JH; Diamond SL Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011 [TBL] [Abstract][Full Text] [Related]
16. Biochemical and biophysical conditions for blood clot lysis. Sabovic M; Blinc A Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642 [TBL] [Abstract][Full Text] [Related]
18. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. Pannell R; Black J; Gurewich V J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831 [TBL] [Abstract][Full Text] [Related]
19. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development. Landskroner K; Olson N; Jesmok G J Vasc Interv Radiol; 2005 Mar; 16(3):369-77. PubMed ID: 15758133 [TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen. Wu JH; Diamond SL J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]